Pharmaceutical AI Training Data Access

Pharma's AI data problem is bigger than anyone admits

Pharmaceutical companies are investing billions in AI for drug discovery, clinical trial optimisation, patient recruitment, and real-world evidence generation. Every one of these applications requires training data — real clinical data — from hospitals, imaging centres, and specialty clinics. And every one of these data sources is locked behind institutional governance that blocks data export.

The pharma industry's standard solution — sponsor-funded clinical studies with prospective data collection — takes years and costs millions per dataset. By the time the data is collected, cleaned, and released for analysis, the AI model architecture has advanced two generations. The data is stale before it reaches the training pipeline.

Use cases for pharma AI on clinical data

• Drug discovery and target identification — train models on real patient genomics, proteomics, and clinical outcomes to identify novel drug targets.
• Patient recruitment for clinical trials — train NLP models on EHR data to identify eligible patients matching complex trial inclusion/exclusion criteria.
• Real-world evidence (RWE) generation — train models on longitudinal patient data to compare treatment effectiveness, safety profiles, and health economic outcomes.
• Biomarker discovery — train models on paired imaging, genomics, and clinical outcomes to identify predictive biomarkers for treatment response.
• Drug repurposing — train models on real-world treatment patterns and outcomes to identify existing drugs with efficacy in new indications.
• Adverse event prediction — train models on real pharmacovigilance data to predict adverse drug reactions before they appear in spontaneous reporting systems.

Why pharma cannot simply buy clinical data

Several well-funded attempts to create clinical data marketplaces have failed or operate at limited scale. The reasons are structural:

• Hospitals cannot sell patient data. GDPR, HIPAA, and NHS governance do not permit the sale of patient data. Data use agreements grant access for specific research purposes — not ownership or commercial resale.
• Patient consent does not transfer. A patient who consents to their data being used for care at Hospital A has not consented to that data being sold to Pharma Company B for AI training.
• Data quality decays with de-identification. The features most valuable for pharma AI — temporal resolution of events, precise geographic and demographic variables, unstructured clinical notes — are the features most damaged by de-identification.

Compute-to-data: pharma trains on hospital data without ever touching it

Rapha Protocol enables a fundamentally different model: the pharmaceutical company submits a model training job. The job executes inside the hospital's edge appliance under SGX/TDX attestation and OPA policy enforcement. The pharma company receives trained model weights — not patient data. The hospital earns 70% of the training fee. The data never moves.

For pharma, this means: faster iteration cycles (train today on yesterday's clinical data), zero PHI custody liability, auditable proof receipts for regulatory submissions, and per-job settlement that aligns incentives between pharma R&D budgets and hospital data custodians.

Regulatory implications

For pharma companies submitting AI/ML models to regulators (FDA, EMA, MHRA), the provenance of training data is increasingly scrutinised. Rapha Protocol's cryptographic proof receipts provide auditable evidence of: which dataset was used (dataset manifest hash), which model architecture was trained (container digest hash), how many records were processed (RaphaDataLoader count), that raw PHI was not exported (zeroRawPhiExported field), and when and where training occurred (Polygon block timestamp).

This audit trail — anchoring training evidence on a public blockchain while keeping clinical data private — is specifically designed to support regulatory submissions for AI/ML-enabled medical devices and drug development tools.